MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Sewall

Status: Enrolling

ClinicalTrials.gov Number: NCT06152575

Phone: 346.238.2674

Protocol Number: PRO00037922

Description

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer).
More to Explore